# 1 Single-Cell Analysis Reveals Macrophage-Driven T Cell

2

# **Dysfunction in Severe COVID-19 Patients**

3 **Running title:** M2 macrophages orchestrate T cell dysfunction in COVID-19

4

Xiaoqing Liu<sup>1#</sup>, Airu Zhu<sup>1#</sup>, Jiangping He<sup>2,3#</sup>, Zhao Chen<sup>1#</sup>, Longqi Liu<sup>4,5#</sup>, Yuanda Xu<sup>1#</sup>,
Feng Ye<sup>1</sup>, Huijian Feng<sup>2,3</sup>, Ling Luo<sup>1</sup>, Baomei Cai<sup>2,3</sup>, Yuanbang Mai<sup>2,3</sup>, Lihui Lin<sup>2,3</sup>,
Zhenkun Zhuang<sup>4,5</sup>, Sibei Chen<sup>1</sup>, Junjie Shi<sup>2,3</sup>, Liyan Wen<sup>1</sup>, Yuanjie Wei<sup>2,3</sup>, Jianfen
Zhuo<sup>1</sup>, Yingying Zhao<sup>2,3</sup>, Fang Li<sup>1</sup>, Xiaoyu Wei<sup>4,5</sup>, Dingbin Chen<sup>1</sup>, Xinmei Zhang<sup>6</sup>, Na
Zhong<sup>6</sup>, Yaling Huang<sup>4,5</sup>, He Liu<sup>2,3</sup>, Jinyong Wang<sup>2,3</sup>, Xun Xu<sup>4,5</sup>, Jie Wang<sup>2,3</sup>, Ruchong
Chen<sup>1</sup>, Xinwen Chen<sup>2,3</sup>, Nanshan Zhong<sup>1</sup>, Jingxian Zhao<sup>1\*</sup>, Yi-min Li<sup>1\*</sup>, Jincun
Zhao<sup>1,7\*</sup>, Jiekai Chen<sup>2,3,8\*</sup>

12

<sup>1</sup>State Key Laboratory of Respiratory Disease, National Clinical Research Center for
Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated
Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China 510120
<sup>2</sup>Guangzhou Regenerative Medicine and Health-Guangdong Laboratory (GRMHGDL), Guangzhou, China 510530
<sup>3</sup>Key Laboratory of Regenerative Biology of the Chinese Academy of Sciences and
Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine,

20 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences,

- 21 Guangzhou, China 510530
- 22 <sup>4</sup>BGI-Shenzhen, Shenzhen, China 518083
- <sup>5</sup>China National GeneBank, BGI-Shenzhen, Shenzhen, China 518120

<sup>6</sup>Becton Dickinson Medical Devices (Shanghai) Co., Ltd, Guangzhou, Guangdong,

25 China 510180

<sup>7</sup>Institute of Infectious disease, Guangzhou Eighth People's Hospital of Guangzhou

- 27 Medical University, Guangzhou, China 510060
- 28 <sup>8</sup>Lead Contact
- 29
- 30 *#*These authors contributed equally to this work.
- 31
- 32 \*Corresponding authors. Emails: <u>chen\_jiekai@gibh.ac.cn</u> (J.C.), <u>zhaojincun@gird.cn</u>
- 33 (J.Z.), <u>dryiminli@vip.163.com</u> (Y.L.), <u>zhaojingxian@gird.cn</u> (J.Z.)
- 34
- 35 Key words: COVID-19, SARS-CoV-2, Macrophage, Virus-specific T cell, Exhaustion

#### 36 SUMMARY

37 The vastly spreading COVID-19 pneumonia is caused by SARS-CoV-2. 38 Lymphopenia and cytokine levels are tightly associated with disease severity. 39 However, virus-induced immune dysregulation at cellular and molecular levels 40 remains largely undefined. Here, the leukocytes in the pleural effusion, sputum, and 41 peripheral blood biopsies from severe and mild patients were analyzed at single-cell 42 resolution. Drastic T cell hyperactivation accompanying elevated T cell exhaustion 43 was observed, predominantly in pleural effusion. The mechanistic investigation 44 identified a group of CD14<sup>+</sup> monocytes and macrophages highly expressing CD163 45 and MRC1 in the biopsies from severe patients, suggesting M2 macrophage 46 polarization. These M2-like cells exhibited up-regulated IL10, CCL18, APOE, CSF1 47 (M-CSF), and CCL2 signaling pathways. Further, SARS-CoV-2-specific T cells were 48 observed in pleural effusion earlier than in peripheral blood. Together, our results 49 suggest that severe SARS-CoV-2 infection causes immune dysregulation by inducing 50 M2 polarization and subsequent T cell exhaustion. This study improves our 51 understanding of COVID-19 pathogenesis.

# 52 **INTRODUCTION**

53 Coronavirus Disease 2019 (COVID-19) caused by a novel coronavirus, severe 54 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in 55 December 2019 in Wuhan, Hubei Province, China. As of April 24, 2020, a total of 56 2,626,321 cases with 181,938 deaths have been confirmed globally, as reported by 57 the World Health Organization (WHO). This pandemic has quickly become a 58 unprecedent major public emergency of global concerns (Chan et al., 2020; Chen et 59 al., 2020; Huang et al., 2020; Li et al., 2020b).

60 Most COVID-19 patients experience mild symptoms. However, a significant 61 proportion of the patients develop severe pneumonia and require ventilator-assisted 62 breathing (Guan et al., 2020; Huang et al., 2020; Wang et al., 2020). Patients with 63 severe diseases have significantly higher levels of inflammatory response in their 64 plasma compared to patients with mild disease, indicating dysregulation of immune 65 responses (Huang et al., 2020). A recent autopsy study of COVID-19 patients has 66 also revealed macrophage infiltration and excess production of mucus in the infected 67 lungs, especially in the damaged small airways and alveoli (Liu et al., 2020b).

68 Upon respiratory CoV infection, properly regulated immune response is essential 69 to control and eliminate the virus as well as to improve clinical outcome (Braciale et 70 al., 2012), whereas maladjusted immune responses may result in immunopathology 71 and impaired pulmonary gas exchange (Chen and Subbarao, 2007; de Wit et al., 72 2016; Li et al., 2020a). Increased levels of serum proinflammatory cytokines (e.g., IL-73 1 $\beta$ , IL-6, IL-12, IFN- $\gamma$ , IP-10, and MCP-1) are associated with pulmonary 74 inflammation and extensive lung damage in SARS patients (Wong et al., 2004). 75 Meanwhile, another set of proinflammatory cytokines, including IFN-y, TNF, IL-15. 76 and IL-17 were induced in Middle East Respiratory Syndrome coronavirus (MERS-77 CoV) infection (Mahallawi et al., 2018). The disease-specific cytokine profiles indicate

78 that different host immune factors play a role in the pathogenesis of these highly 79 pathogenic CoV infections. A recent study has reported that serum inflammatory 80 cytokine profiles in severe COVID-19 patients is similar to that of SARS-CoV 81 infection, with elevated concentrations of IL-1 $\beta$ , IFN- $\gamma$ , IP-10, and MCP-1 (Huang et 82 al., 2020). In addition, either cytokine storm-relevant factors such as G-CSF and TNF, 83 or Th2-related cytokines such as IL-4 and inhibitory IL-10, were found with SARS-84 CoV-2 infection (Huang et al., 2020). These results suggest that overall balance of 85 immune responses may be important in disease progression and host recovery from 86 respiratory CoV infections.

87 In SARS-CoV infected mice, we have found that exuberant inflammatory 88 responses and lung damage associated with dysregulated cytokine response induce 89 the accumulation of pathogenic inflammatory monocyte-macrophages (IMMs) in the 90 lung. The IMMs not only elevated lung cytokine/chemokine levels but also inhibited 91 SARS-CoV-specific T cell responses in mice, leading to delayed viral clearance and 92 deteriorated clinical outcomes (Channappanavar et al., 2016). In MERS-CoV-infected 93 mice, early type-I interferon treatment (IFN-I) was protective, whereas delayed IFN-I 94 treatment failed to effectively inhibit virus replication, increased infiltration and 95 activation of monocytes and macrophages in the lungs, and enhanced 96 proinflammatory cytokine expression, resulting in fatal pneumonia (Channappanavar 97 et al., 2019). These studies suggest that not only proper cytokine response but also 98 inflammatory monocytes and/or macrophages play crucial roles in the respiratory 99 CoV pathogenesis.

100 CoV-specific T cells are required for viral clearance and for protection from 101 clinical disease (Channappanavar et al., 2014; Zhao et al., 2010). We have shown in 102 a mouse model that SARS-CoV-specific CD4<sup>+</sup> T cells in the airway promoted anti-103 viral innate immune response and viral-specific CD8<sup>+</sup> T cell response by increasing

104 respiratory dendritic cell migration from the lung to the draining lymph nodes (Zhao et 105 al., 2016). In MERS-CoV infection, the recovery of patients from MERS is also 106 associated with CD8+ T cell responses. MERS patients with robust viral-specific 107 CD8+ T cell response in peripheral blood mononuclear cell (PBMC) but not viral-108 specific CD4<sup>+</sup> T cell response spent a shorter period in the ICU (Zhao et al., 2017). It 109 is likely that T cell responses also play an important role in viral clearance and host 110 recovery from SARS-CoV-2 infection. However, the phenotype and function of T cells, 111 their behavior in the proinflammatory microenvironment, and their interaction with 112 other immune cells have not been elucidated in COVID-19 patients, particularly T 113 cells in human lungs which are most relevant clinically yet difficult to obtain from 114 human patients compared to PBMC.

115 Here, by integrating advanced single-cell technology and immunological 116 approaches, leukocytes derived from the pleural effusion, sputum, and peripheral 117 blood biopsies of severe and mild COVID-19 patients were analyzed. SARS-CoV-2-118 specific T cells were detected in pleural fluid mononuclear cells (PFMC) earlier than 119 in PBMC and correlated with viral clearance. Immune dysregulation and T cell 120 exhaustion were observed, together with accumulation of T cell suppressive M2-121 macrophages in PFMC. Further analyses suggested that severe SARS-CoV-2 122 infection induced M2-macrophage polarization in the lung that might play a role in 123 driving T cell exhaustion. These findings and mechanistic insights not only improved 124 our understanding of COVID-19 pathogenesis and mechanism for immune 125 dysregulation, but also demonstrated the value of pleural effusion in translational 126 research with implications for disease diagnostics and treatment.

#### 127 **RESULTS**

# scRNA-seq revealed distinct immune cell composition and state in the COVID-129 19 patient

A 70s old man infected with SARS-CoV-2 (confirmed by real-time PCR) developed 130 131 severe pneumonia and was admitted to the intensive care unit (ICU) of the First 132 affiliated hospital of Guangzhou Medical University. Invasive ventilator-assisted 133 breathing was instituted at 9 days post symptom onset (d.p.o.). Thymosin (Zadaxin) 134 treatment was started from 10 d.p.o. Pleural effusion was observed at 19 d.p.o. and 135 drainage tube was placed. Pleural fluid (at 20 d.p.o.) and serial peripheral blood were 136 collected (Figure 1A). To characterize the immune responses in humans upon SARS-137 CoV-2 infection, single-cell RNA-sequencing (scRNA-seq) was performed on the 138 patient's paired pleural fluid mononuclear cells (PFMC) and peripheral blood 139 mononuclear cells (PBMC) obtained at 20 d.p.o. Passing through rigorous quality-140 control processes, the transcriptome profiles of 7,587 PFMC and 3,874 PBMC cells 141 were subjected to subsequent analysis (Figures 1B and S1A). A PBMC scRNA-seq 142 dataset (Zheng et al., 2017) composed of 9,707 cells from a healthy individual was 143 repurposed and integrated as a control, denoted H-PBMC. Most cell types were 144 conserved among the PFMC, PBMC, and H-PBMC samples, including CD4+/CD8+ T 145 cell subsets, B cells, NK cells, monocytes and macrophages, to a much less extent 146 dendritic cells (DC) and plasmacytoid DC (pDC) (Figures 1C-E, S1B). Consistent 147 with the finding of lymphopenia reported in other COVID-19 patients (Diao et al., 148 2020; Liu et al., 2020a), absolute cell count assay showed that CD8<sup>+</sup>T cell numbers 149 in the patient's blood dropped far below the normal range (Figure S1C), with only a 150 slight decrease for CD4+T cells and NK cells, and no significant change for B cells 151 (Figure S1C), resulted in increased CD4+/CD8+ T cell ratios in both PBMC and PFMC 152 comparing to H-PBMC (Figure S1D). CCR7+ naïve CD4+ T cells were predominant in 153 the patient's PBMC, while PFMC contained more activated CD4<sup>+</sup> T and CD8<sup>+</sup> T cells 154 by frequency (Figures 1C,1D, S1D and S1E). The percentage of FOXP3+CD25+ Treq 155 and CD25 expression were higher in PFMC, and a group of IL10<sup>+</sup> T cells was exclusive in the patient's PFMC (Figures 1C, 1D and S1F and S1G). Conventional 156 157 cell lineage markers and flow cytometry analysis further validated the clustering and 158 annotation results (Figures 1D, 1E and S1B). These data reflected the changes in immune cell composition in pulmonary and peripheral in response to viral infection. 159 160 Of note, the expression of SARS-CoV-2 entry receptor angiotensin-converting 161 enzyme II (ACE2) was also examined in scRNA-seq (Zhou et al., 2020). Minimal 162 ACE2 expression was found in all immune cell types (Figure S1H).

163

# 164 Significant T cell hyperactivation and exhaustion were detected in the COVID-

# 165 **19 patient**

166 To investigate signaling transduction regulation associated with SARS-CoV-2 167 infection in human, ligand-receptor interaction analysis among seven major cell types (i.e., naive/activated CD4+/CD8+ T cell, NK cell, macrophage, and monocyte) was 168 169 performed. More interactions were instigated than abolished upon infection (Figures 170 2A and S2A). Explicitly, CCR5-associated pathways involving chemokines CCL3, 171 CCL4, CCL5 and CXCR4 were induced in the activated CD8+ T cells in the patient's 172 PFMC and PBMC, prominently in PFMC, suggesting CD8<sup>+</sup> T cell hyperactivation 173 (Figures 2A-C and S2B) (Contento et al., 2008; Dairaghi et al., 1998; Honey, 2006; 174 Trifilo et al., 2003). The CCL2-CCR4 pathway was initiated in the activated CD4+ 175 population accompanied by an elevated fraction of activated CD4<sup>+</sup> cells which was 176 observed exclusively in PFMC (Figures 2B-2D and S2B). This was further confirmed 177 by flow cytometry analysis showing a higher proportion of CD4<sup>+</sup> T cells expressed 178 CCR4 in PFMC than in PBMC (Fig. S2C). CCR4 is a key chemokine receptor guiding 179 T cell to the lung (D'Ambrosio et al., 2001), suggesting CCR4-expressing T cells 180 would be preferentially recruited to the infected site. We also observed mild and 181 strong induction of activated T-cell (CD38+HLA-DR+) population in PBMC and PFMC, 182 respectively (Figures 2D). Of note, the majority of these activated T cells highly 183 expressed PD-1 (Figure 2E), suggesting T-cell exhaustion upon activation. The 184 percentage of CD38+HLA-DR+PD1+ triple-positive CD4+ and CD8+ cells was 185 significantly higher in PFMC than in the patient's PBMC indicating massive T-cell 186 exhaustion in PFMC where could more closely reflect the status of T cells in the lung 187 local inflammatory microenvironment (Figure 2F). Consistently, T cell exhaustion 188 markers, PDCD1 (PD1), LAG3, HAVCR2 (TIM3), and PRDM1 had enhanced 189 expression in PFMC in scRNA-seq analysis (Figures 2G and S2D; Table S1). Further, 190 activated T cells in the patient's PFMC and PBMC also lost IL-2, IL-7R and TNF 191 expressions (Figure S2A) which are critical for T cell proliferation, survival, as well as 192 signs for early T cell exhaustion (Wherry et al., 2007; Yi et al., 2010). NK and B cell 193 responses to the infection were also investigated. NK/B cell activation pathway 194 genes including CD160, KLRK1 and CD22 (Clark and Lane, 1991; Haas et al., 2018; 195 Le Bouteiller et al., 2011; Orr and Lanier, 2010) were found to be significantly down-196 regulated in patient's PFMC and PBMC (Figures S2D and S2E; Table S1). Taken 197 together, these results demonstrated that T cells in COVID-19 patients underwent 198 significant hyperactivation and exhaustion upon prolonged SARS-CoV-2 infection, 199 especially in the lung which could contribute to the delayed viral clearance.

200

M2 macrophage-polarization and inhibitory pulmonary environment in the
 severe COVID-19 patient.

To elucidate the mechanism causing changes in T cell function and exhaustion post-SARS-CoV-2 infection in the lung, macrophages in PFMC were scrutinized. CCL2 was highly induced in the PFMC macrophages (Figure 2B) and reported to shape

206 macrophage polarization (Sierra-Filardi et al., 2014), so monocytes and 207 macrophages in the COVID-19 patient's samples were then analyzed. GO term 208 analysis of macrophages confirmed that negative regulators of immune response 209 were selectively enriched in PFMC, while T cell activators were enriched in PBMC 210 and H-PBMC (Figures S3A-S3C). Consistently, anti-inflammatory factors (Stoger et 211 al., 2012), including the M2-macrophage markers, CD163 and CD206 (MRC1) 212 (Mantovani et al., 2002), exhibited elevated expression levels on monocytes and 213 macrophages in PFMC, whereas pro-inflammatory marker expression levels were 214 decreased or unaltered (Figures 3A, 3B and S3A). M2 macrophages are key players 215 in T cell exhaustion in the tumor microenvironment and chronic viral infections (Jiang 216 et al., 2015). The potential M2-macrophage polarization event was further validated 217 by elevated expression of M2 polarization regulatory components in PFMC, including 218 CCL2, CSF1, and SPP1 in monocytes as well as APOE, IL10, and CCL18 in 219 macrophages. (Deng et al., 2018; Murray, 2017; Sierra-Filardi et al., 2014; Svensson-220 Arvelund et al., 2015; Wang et al., 2019; Zhang et al., 2017) (Figures 3C and 3D). 221 APOE and IL-10 are known to induce T cell exhaustion (Deng et al., 2018; Pestka et 222 al., 2004; Yi et al., 2010). Notably, these molecules represented most of the PFMC-223 specific associations with their receptors upon viral infection (Figures 2A and 2B). 224 Flow cytometry analysis of CD14<sup>+</sup> monocytes and macrophages in PFMC also 225 demonstrated the presence of CD206<sup>+</sup> and CD163<sup>+</sup> populations which were 226 consistent with M2 macrophage phenotype (Figure S3D) (Mantovani et al., 2002). 227 Interestingly, the majority of CD163<sup>+</sup> cells express PD-1 while CD206<sup>+</sup> cells express 228 TIM-3, and Poly I:C induced IL-10 expression was primarily found in CD206+TIM-3<sup>high</sup> 229 cells (Figure S3D). Moreover, CCL-2 and IL-10 concentrations were higher in pleural 230 effusion than those in patient plasma, agreeing with the M2 macrophage-driven 231 microenvironment (Figure 3E). Collectively, these results supported the notion that

- 232 M2 macrophages polarized pulmonary microenvironment potentially contributed to T
- cell dysfunction in the severe COVID-19 patient (Figure 3F).
- 234

# 235 Characterization of SARS-CoV-2-specific T cell responses in pleural effusion

#### and peripheral blood biopsies of the COVID-19 patient.

To characterize virus-specific T cell responses in the patient, PFMCs and PBMCs 237 238 were stimulated with SARS-CoV-2-specific peptide pools in the presence of brefeldin 239 A. Enhanced number and percentage of viral-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, determined by IFN-y expression, were observed in PFMC at 20 *d.p.o.* However, 240 virus-specific T cells were absent in PBMC until later d.p.o. and slowly increased 241 242 over time (Figures 4A and 4B). Immunocompetent CoV-specific T cells tend to produce multiple cytokines upon peptide stimulation (Zhao et al., 2017). We 243 244 previously found that in MERS convalescent patients, most of the MERS-CoV-245 specific T cells co-produced IFN- $\gamma^+$  and TNF+ (Zhao et al., 2017). To evaluate the 246 functionality of virus-specific T cells in this patient, co-expression of TNF by IFN- $\gamma^+$  T 247 cells was examined. Most of the virus-specific CD4+ and CD8+ T cells did not 248 produce TNF in PFMC at 20 d.p.o. and in PBMC at 29 d.p.o. which was consistent 249 with an exhaustion phenotype (Yi et al., 2010) (Figure 4C). The percentage of IFN- $\gamma^+$ 250 TNF<sup>+</sup> virus-specific T cells increased in PBMC at 38 d.p.o. when the patient's 251 condition improved (Figure 1A). Of note, most of the IFN- $\gamma^+$  or IFN- $\gamma^+$ TNF<sup>+</sup> cells in 252 PFMC were CD38+HLA-DR+ which were much higher than those in PBMC (Figure 253 S4A), indicating virus-specific T cells were hyperactivated in the pleural effusion. 254 Finally, the longitudinal elevation of both numbers and functionality of virus-specific T 255 cells were correlated with decreased viral loads in throat swab and sputum 256 specimens (Figure 4D) and disease amelioration (Figure 1A), indicating T cells were 257 required for protection from clinical disease and virus clearance.

258

#### 259 Corroboration of M2-Polarization in the Sputa of Severe COVID-19 Patients

260 To validate the macrophage-driven T cell suppression observed in the severe 261 COVID-19 patient's PFMC, sample size was expanded by including cells isolated 262 from sputum samples from 4 patients, with 2 severe and 2 mild cases (Figure 5A; 263 Table S2). scRNA-seq of these samples revealed 4 major cell types, B cells, epithelia, 264 macrophages, and monocytes (Figures 5B, 5C and S5A). Intriguingly, two samples 265 from severe cases were composed of a larger macrophage population and lower 266 percentages of B cells and epithelia than those in mild patients (Figure 5D). 267 Consistent with PFMC, the anti-inflammatory M2 macrophage markers exhibited 268 higher expression, whereas the pro-inflammatory markers displayed lower mRNA 269 levels in the sputa of the severe COVID-19 patients (Figures 5E, S5B and S5C). 270 Besides, elevated expression of M2-polarization markers further verified the M2 271 macrophage activation events in the severe cases and highlighted the stage-specific 272 immune response post-SARS-CoV-2 infection (Figure 5F and S5D). Flow cytometry 273 analysis of CD14<sup>+</sup> leukocytes showed increased M2 macrophages in the severe 274 COVID-19 patient comparing to the mild cases (Figure 5G). In addition, the 275 percentage of M2 cells and M2 polarization related cytokines in sputum were 276 decreased when the severe patient's condition improved (Figures 5H and 5I), 277 indicating the correlation between M2 cell activation and disease severity.

#### 278 **DISCUSSION**

SARS-CoV-2 is the causative pathogen of COVID-19 pneumonia (Zhou et al., 2020). The elderly and individuals with comorbidities are at higher risk for severe disease (Guan et al., 2020; Li et al., 2020b). No drug or vaccine has yet been approved for human use due to the lack of understanding of disease pathogenesis and immune responses in human.

284 Our study provides a framework to systematically investigate immune profile 285 in COVID-19 patient-derived PFMC and sputum biopsies. By integrating advanced 286 single-cell technology and immunological approaches, M2-macrophage polarization-287 driven T cell exhaustion upon viral infection in the lung was mechanistically revealed 288 suggesting T cell suppression and dysregulation in infection site of severe COVID-19 289 cases. SARS-CoV-2-specific T cells were also detected in PFMC earlier than in 290 PBMC of the patient, demonstrating the advantage of utilizing PFMC biopsies. The 291 sensitivity and reliability of PFMC over PBMC had been underlined throughout this 292 study. In addition to the earlier emergence of the SARS-CoV-2-specific T cell 293 population, PFMC also encompassed a higher number of hyperactivated T cells. A 294 group of CD14<sup>+</sup> M2 macrophage-like cells highly expressing M2 polarization markers. 295 and as well as T cells expressing exhaustion markers were also exclusively found in 296 PFMC. Comparing to the subtle hints from PBMC, PFMC served as a robust tool and 297 provided consistent mechanistic evidence of immune dysregulation.

As excess fluids in the pleural cavity surrounding the lungs, pleural effusion had been found to associate with severe pulmonary infections, including MERS (Das et al., 2015) and COVID-19 (Shi et al., 2020). Pulmonary pathological microenvironment had been reported to increase the permeability of the capillaries in the lung, leading to exudate pleural effusion (Porcel and Light, 2006, 2008). Thus, PFMC was reasoned to share closer immune properties in the SARS-CoV-2-infected 304 lungs in human and a better indicator of the pulmonary inflammatory 305 microenvironment. Further, post-mortem examination of a severe COVID-19 case 306 illustrated thickened pleura with extensive adhesion to the lung tissue (Liu et al., 307 2020b) suggesting the involvement of pleura and pleural fluids in disease 308 pathogenesis. These evidences supported our conclusion and highlighted the 309 translational value of this study.

310 The cutting-edge single-cell analysis of the PFMC biopsy facilitated the 311 profiling of the heterogeneous immune response in the patient. Through ligand-312 receptor interaction analysis, enhanced T cell activation and exhaustion pathways 313 were accompanied by the elevation of their mRNA expression levels. Furthermore, 314 augmented M2 polarization markers in the monocytes and macrophages 315 mechanistically linked T cell exhaustion with M2 macrophage activation, reflecting 316 virus-induced T cell suppression, which is consistent with our previous finding that 317 alveolar macrophages play inhibitory roles on virus-specific T cells in SARS-CoV infected mice (Zhao et al., 2009). Although prevailing perspectives had associated 318 319 exuberant inflammatory response with severe CoV cases (Mahallawi et al., 2018; 320 Wong et al., 2004), COVID-19 exhibited distinct pathological phenotypes indicating it 321 has distinct immune properties after infection. In contrast to SARS, the COVID-19 322 autopsy displayed less fibrosis, suggesting a dampened release of pro-inflammatory 323 factors (Biswas et al., 2011). Huang et al. also reported the increased secretion of 324 immunosuppressive cytokines, IL-4 and IL-10, demonstrating a COVID-19-specific 325 cytokine profile (Huang et al., 2020). In a mouse model of SARS-CoV infection, 326 STAT-I was also found to induce M2 polarization, causing pulmonary damage (Page 327 et al., 2012). These pathological and immunological analyses supported that immune 328 dysregulation and dysfunction contributed to COVID-19-specific pathogenesis, 329 echoing our observations in the severe COVID-19 cases.

330 Our findings unveiled that the immunoinhibitory pulmonary environment 331 driven by M2 macrophage polarization induced T cell suppression in severe COVID-332 19 patients, suggesting anti-M2 treatment as a potential therapeutic strategy. Some 333 approved anti-M2 strategy has already achieved good clinical outcomes in anti-tumor 334 therapy (Tarig et al., 2017). Agents such as targeting of IL-10, CCL2, and CSF 335 signaling axis have demonstrated efficacy in preclinical breast cancer (Germano et 336 al., 2013; Tarig et al., 2017; Zollo et al., 2012). Alternatively, enhancing M1 with anti-337 CD40 or CD25 monoclonal antibody (mAb) to suppress M2 polarization has also 338 been reported (Buhtoiarov et al., 2005; Jacobs et al., 2010; Tarig et al., 2017). 339 Besides, severe COVID-19 patients in our hospital were regularly treated with 340 Thymosin (Zadaxin), a T cell stimulator which has been shown to stimulate T cell 341 development, differentiation and proliferation (Costantini et al., 2019; Garaci et al., 342 1995; Jiang et al., 2011). After Zadaxin treatment, increased NK and CD8 T cell 343 numbers and partially reversed T cell exhaustion were observed, indicating Zadaxin 344 could potentially restore T cell function (Figures S1C and Fig 4C).

345 Lymphopenia had been considered as a signature of severe COVID-19 346 infection (Bermejo-Martin et al., 2020). Meanwhile, impaired lymphatic tissue in 347 spleen and lymph node shrinkage was observed in a COVID-19 autopsies (Liu et al., 348 2020b), indicating massive damage of immune system. Integrating our findings, to 349 maintain the proliferation and functionality of T cells before the massive immune 350 suppression would prevent the deterioration of disease. Conversely, the progression 351 of T cell suppression could lead to excessive T cell exhaustion, and consequently, 352 result in delayed viral clearance.

In conclusion, our study utilized the pleural effusion and sputum biopsies derived from severe COVID-19 cases to dissect the heterogeneity of immune response upon SARS-CoV-2 infection in human. Specifically, strong mechanistic

356	evidence	of	M2	macrophage-driven	Т	cell	exhaustion	was	elucidated.	Further	
-----	----------	----	----	-------------------	---	------	------------	-----	-------------	---------	--

- 357 analysis of the correlation between T cell suppression and disease development
- 358 demonstrated that the value of pleural effusion and sputa in translational research
- and providing mechanistic implications for disease diagnostics and treatment.








Figure 1. A Comprehensive Survey of Single Cell Reveals Unique Immune State for the COVID-19 Patient.


- (A) Schematic diagram showing the timeline of disease course of the patient.
- (B) Schematic diagram showing the isolation of pleural fluid mononuclear cells (PFMC) and peripheral blood mononuclear cells (PBMC) from the COVID-19 patient. Single-cell sequencing was taken by 10x platform.
- (C) (Left) UMAP plots visualizing single-cell RNA-seq data of 7,587 PFMC single cells and 3874 PBMC single cells from the COVID-19 patient and 9,707 PBMC single cells from a healthy donor (H-PBMC).
   (Right) Differences in cellular composition among PFMC, PBMC and H-PBMC.
- (D) UMAP plots showing the expression of maker genes for particular cell types. Gene expression levels are indicated by shades of red.
- (E) Flow cytometry dot plots showing the identification of various leukocyte subpopulations in the PFMC.





# Figure S1. Identification of Cell Types for COVID-19 Patient.


- (A) Violin plots showing the raw counts number and the numbers of detected genes by scRNA-seq for each cell.
- (B) Dot plots showing the expression level and the percent of cells the gene is expressed in, for the indicated marker genes.
- (C) Absolute CD4/8<sup>+</sup>T cell (upper) and NK/B cell (lower) counts (cells/mL) in the patients' pleural fluid and peripheral blood collected at the indicated times post-onset are shown. The red and blue dashed lines represent the normal range of CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts respectively.
- (D) Bar graphs showing the indicated ratios across samples.
- (E) Flow plots showing CCR7 and CD45RA expression by CD4<sup>+</sup> and CD8<sup>+</sup> T cells from the patient's PBMC and PFMC.
- (F) Violin plots showing the expression of IL2RA in Treg cells (upper) and IL10 in IL10+ T cells (lower) defined from Figure 1C.
- (G) (left) PFMCs were stimulated with PMA and ionomycin for 4 hours in the presence of brefeldin A. IL-10 expression by a small population of T cells were detected by intracellular cytokine staining; (right) A flow pot showing CD4+CD25+CD127<sup>low</sup> regulatory T cells present in the PFMC.
- (H) UMAP plots showing the expression of ACE2 and SARS-CoV-2. Gene expression levels are indicated by shades of red.



CD8+ T

#### Figure 2. Multiple Regulatory Immune Responses for COVID-19 patient.


- (A) Circos plots showing the ligand-receptor interactions across different cell types. The outermost ring represents different cell types according to the color bar. The innermost color lines represent ligand-receptor contacts in indicated cell types, the line thickness represents the contact strength. The adjacent black ring shows ligand-receptor interaction strength changes in between indicated samples. The next black ring represents the expression changes of indicated genes in the indicated cell types.
- (B) Overview of ligand-receptor interactions of selected cytokines, P-value indicated by the dot size. The product of the means of average expression level of molecule 1 (ligand, green) and molecule 2 (receptor, red) are indicated by color.
- (C) Violin plots showing the expression changes of selected genes in the indicated cell types.
- (D) Flow cytometry dot plots showing the expression of CD38 and HLA-DR by CD4+ and CD8+ T cells.
- (E) Flow cytometry dot plots showing PD-1 expression by CD38<sup>+</sup>HLA-DR<sup>+</sup> activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells.
- (F) Percentage of CD38+HLA-DR+PD-1+ triple positive cells in total CD4+ and CD8+ T subsets.
- (G) Violin plots showing the expression changes of T cell exhaustion and cytotoxicity- related genes in activated CD4/8<sup>+</sup> populations across different samples.



# Figure S2. Virus-induced responses in COVID-19 patient.


- (A) Circos plots showing the ligand-receptor interactions across different cell types. The outermost ring represents different cell types according to the color bar. The innermost color lines represent ligand-receptor contacts in indicated cell types, the line thickness represents the contact strength. The adjacent black ring shows ligand-receptor interaction strength changes in between indicated samples. The next black ring represents the expression changes of indicated genes in the indicated cell types.
- (B) UMAP plots showing the expression of indicated genes, Gene expression levels are indicated by shades of red.
- (C) Flow histograms showing CCR4 expression by CD4<sup>+</sup> T cells.
- (D) Heatmaps showing the differentially expressed genes in indicated cell types across different cell types.
   Selected genes are indicated on the right.
- (E) Gene ontology (GO) analysis for the differential expressed genes from panel D.

# Figure 3




# Figure 3. Single-Cell RNA-seq Reveals Unique Macrophage Types Associated with COVID-19 patient.

- (A) Heatmap showing the differentially expressed genes for macrophages and monocytes between the COVID-19 patient and the healthy donor.
- (B) Violin plots showing the expression of pro-inflammatory and anti-inflammatory factors between the COVID-19 patient and the healthy donor in the indicated cell types.
- (C) Violin plots showing the expression of indicated genes in monocytes across different cell types.
- (D) Violin plots showing the expression of indicated genes in macrophages across different cell types.
- (E) Concentrations of MCP-1 and IL-10 in the patient's plasma at the indicated d.p.o. and in the pleural fluid were quantified using BD Cytometric Bead Array (CBA) assay.
- (F) A model of SARS-CoV-2 pathogenesis. SARS-CoV-2 infects pneumocytes and induces monocyte production of cytokines (MCP-1, M-CSF) that mediate M2 polarization. Activated M2 produce APOE, IL-10 and CCL18 that can inhibit activated T cells and induce T cell exhaustion, leading to the virus immune evasion.



D

#### Gated on CD14+ Monocytes/Macrophages



## Figure S3. Unique macrophages in COVID-19 patient.

- (A) Heatmap showing the differentially expressed genes in macrophages from different cell origins. Selected genes are indicated on the right.
- (B) Gene ontology analysis for PFMC specifically high expression genes from panel A.
- (C) Violin plots showing the differential expression of humoral immune response negative regulationrelated genes in macrophages between difference samples.
- (D) CD14<sup>+</sup> cells in the patient's pleural fluid were analyzed for M2 macrophage markers CD206 and CD163 as well as inhibitory markers PD-1 and TIM-3. IL-10 was detectable in TIM-3<sup>high</sup> CD14<sup>+</sup> cells when PFMCs were stimulated with Poly I:C for 4 hours in the presence of brefeldin A.

### Figure 4





Figure 4. Characterization of virus-specific T cell responses in the pleural fluid and in the peripheral

# blood.

- (A) PFMCs and PBMCs obtained at the indicated times post-onset were stimulated with the SARS-CoV-2 peptide pool for 8 hours in the presence of brefeldin A. Virus-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were identified by intracellular IFN-γ staining. No pep, no peptide control.
- (B) Frequencies and numbers (cells/mL) of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the patient's peripheral blood and pleural fluid are shown.
- (C) Flow cytometry dot plots and a bar graph showing the percentages of virus-specific (IFN- $\gamma^+$ ) CD4+ and CD8+ T cells that co-express TNF.
- (D) Viral loads in the patient's sputum and throat swab samples at the indicated times post-onset were shown.

Α




# Figure S4 Anti-viral T Cell Responses.

(A) Flow plots showing CD38 and HLA-DR expression by IFN-γ+TNF+ and IFN-γ+TNF- virus-specific CD4+

and CD8<sup>+</sup> T cells from the patient's pleural fluid and peripheral blood.






# Figure 5. Corroboration of M2-Polarization in the Sputa of Severe COVID-19 Patients

- (A) A summary table of the sputum sample information, including sequenced cell numbers and patients' disease states. Single-cell RNA-seq was performed using the 10X Genomics Chromium system.
- (B) UMAP plots visualizing a total of 20,091 cells analyzed by single-cell RNA-seq and clustered according to their transcriptomic similarity. Distribution of single cells by cell types (the left panel) and source (the right panel) were displayed.
- (C) UMAP plots showing the expression of maker genes for all cell types in (B). A higher gene expression level is indicated by a darker shade of red.
- (D) A 100% stacked column graph displaying the distribution of cell types in each COVID-19 patient.
- (E) Violin plots demonstrating the expression profiles of pro-inflammatory and anti-inflammatory marker genes in the patients' macrophages.
- (F) Violin plots illustrating the expression profiles of M2-polarization genes in the macrophages of each patient.
- (G) CD14<sup>+</sup> cells in the severe and mild patient's sputum were analyzed for M2 macrophage markers CD206 and CD163.
- (H) Sputum obtained at the indicated times post-onset were analyzed for M2 macrophage markers CD206 and CD163.
- M2 polarization related cytokines (IL-10, G-CSF and MCP-1) in sputum were analyzed at the indicated times post-onset.

Figure S5



# Figure S5. Single-cell Transcriptomic Profiles of Sputum Samples From 4 COVID-19 Patients

- (A) Violin plots portraying the expression of classic markers for each identified cell types, validating the cell type annotation in Figure 5B.
- (B) A heatmap showing the differentially expressed genes in the macrophages of the mild (green) and severe (red) COVID-19 cases. Yellow and purple colors represent high and low expression levels, respectively. Selected genes are highlighted on the right.
- (C) Violin plots displaying the expression of pro-inflammatory (i.e., TNF, TNFAIP3, TNFRSF1B, and TNIP1) and anti-inflammatory (i.e., C1QA, C1QB, C1QC, and CCL18) markers in the macrophages of mild (green) and severe (red) COVID-19 patients.
- (D) UMAP plots showing the expression of M2-polarization genes. A higher gene expression level is indicated by a darker shade of red.

# 360 EXPERIMENTAL PROCEDURES

## 361 **Patient information**

362 A 70s old man was laboratory-confirmed positive for novel coronavirus (SARS-CoV-2) 363 infection by real-time PCR. After a 9-day treatment in an isolation ward, the patient 364 became critically ill with respiratory failure and multiple organ dysfunctions, and was 365 transferred to the intensive care unit (ICU) of the First Affiliated Hospital of 366 Guangzhou Medical University on Feb 3, 2020. Notably, pleural effusion was 367 observed on Feb 13 and a thoracentesis was performed under ultrasound guidance and a draining tube was placed on Feb 14. The respiratory support for this patient 368 369 was successfully switched from invasive mechanical ventilation to non-invasive 370 intermittent positive pressure ventilation on March 1. The patient is still in ICU and 371 gradually recovering now. Additional 3 severe patients and 2 mild patients were also 372 included in this study.

373

#### 374 Study approval

This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University with written consent form acquired from the patient. Patient samples were obtained at the indicated times and clinical information was retrieved from the clinical record.

379

#### **Sample collection and preparation**

Throat swabs, sputum, peripheral blood and pleural fluid samples were collected by professional nurses in the hospital and were processed in a biosafety level 2 plus laboratory with biosafety level 3 personal protection equipment. For RNA detection, 3 mL DMEM medium containing 2% FBS was added to swabs and sputum tubes, and following 2500 rpm, 15-30 sec vortex and 15-30 min standing, the supernatant was

386 collected and added to lysis buffer for RNA extraction. Supernatant from pleural fluid 387 was collected following 400 g, 5 min centrifugation for RNA extraction or cytokine 388 detection, and cells in the pleural fluid (PFMC) were freshly used for 10x single-cell 389 RNA-seq or cryopreserved in liquid nitrogen. Sputa were washed once with equal 390 volume of PBS, supernatant was collected for cytokine analysis. Sputa were then 391 treated with equal volume of 0.2% DTT in PBS and cells were collected by 392 centrifugation. Plasma was collected from peripheral blood and PBMCs were isolated 393 using Leucosep tubes (Greiner) and Ficoll-Paque PLUS (GE Healthcare) according 394 to the manufacturer's instructions. Plasma was stored at -80°C for cytokine detection 395 and PBMCs were freshly used for 10x single cell RNA seg or stored in liquid nitrogen.

396

## 397 Viral load quantification

Nucleic acid of respiratory samples was extracted using a Viral RNA extraction kit from Zybio Inc (Chongqing). An in-house real-time PCR kit targeting the SARS-CoV-2 orf1ab gene region was provided by Zybio Inc. Viral loads in respiratory specimens were measured by qRT-PCR and standardized as PFU/ml relative to a positive control (authentic SARS-CoV-2) with known infectious viral titer.

403

## 404 **Cytokine quantification**

405 Cytokine levels in plasma, sputum and pleural fluid were quantified using BD 406 Cytometric Bead Array (CBA) according to the manufacture's protocol with slight 407 modification. Briefly, 50 μL sample was incubated with 50 μL mixed capture beads 408 and 50 μL detection reagent at RT for 3 hours in the dark. Beads were then washed 409 once with 1 mL wash buffer by centrifugation at 300 g for 5 min. Beads were 410 ultimately suspended in the BD Cytofix fixation buffer instead of Assay Diluent. A 411 single set of diluted standards was used to generate a standard curve for each

412 analyte. Flow cytometry data were acquired on a BD FACSVerse flow cytometer and413 analyzed using FCAP v3.0 software.

414

# 415 **Absolute cell count**

To determine absolute numbers of leukocyte subpopulations in blood, BD Trucount tubes (BD, Catalog No. 340334) were used. Briefly, a 20  $\mu$ L fluorescence-conjugated antibody cocktail was added to the Trucount tube, followed by 50  $\mu$ L fresh whole blood, mixed well and incubated for 15 min at room temperature (RT) in the dark. Then 450  $\mu$ L BD FACS lysing solution (BD, Catalog No. 349202) was added and incubated for 15 min at RT to lyse red blood cells. Samples were analyzed on a FACSVerse flow cytometer.

423

#### 424 SARS-CoV-2 peptide library

425 To generate a SARS-CoV-2 peptide library, the sequence from a reference strain, 426 BetaCoV/Wuhan/IVDC-HB-01/2019 (Accession No. EPI ISL 402119) isolated from a 427 patient during the early SARS-CoV-2 pandemic in Wuhan, China was used. A total of 428 two hundred and eighty 20-mer peptides overlapping by 10 amino acids, covering the 429 four SARS-CoV-2 structural proteins, including the spike (S) glycoprotein, the 430 nucleocapsid (N) protein, and the transmembrane (M) and envelope (E) proteins, 431 were synthesized and used for stimulation of PBMCs and PFMCs in vitro. Virus-432 specific T cell responses were subsequently determined using intracellular cytokine 433 staining assays for interferon-gamma (IFN- $\gamma$ ) and tumor necrosis factor (TNF) 434 expression.

435

### 436 Flow cytometry

437 For surface staining, 10<sup>5</sup> to 10<sup>6</sup> cells were blocked with Fc receptor blocking solution

438 (Biolegend), stained with the indicated antibodies at RT for 15 min, labeled with 439 LIVE/DEAD staining dye (Thermo Fisher), and then fixed with Cytofix Solution (BD Biosciences). For intracellular cytokine staining, 10<sup>5</sup> to 10<sup>6</sup> cells per well were 440 441 cultured in 96-well round-bottom plates at 37°C for indicated times in the presence of 442 brefeldin A (BD Biosciences) and stimulators as follows: for virus-specific T cell 443 stimulation, SARS-CoV-2 peptide pool (0.15~0.3 µM for each individual peptide, 444 GenScript) was used; for bulk T cell stimulation, 50 ng/mL PMA (SIGMA) + 1µg/mL 445 ionomycin (abcam) was used; for macrophage stimulation, 1µg/mL Poly (I:C) 446 (Invivogen) was used to mimic viral RNA. Cells were then labeled for cell surface 447 markers, fixed/ permeabilized with Cytofix/Cytoperm Solution (BD Biosciences), and 448 labeled with anti-intracellular cytokine/protein antibodies. Flow cytometry data were 449 acquired on a BD FACSVerse or a BD Aria III flow cytometer and analyzed using 450 FlowJo software (Tree Star Inc.).

451

452 The following anti-human monoclonal antibodies were use
---

Antibody	Fluorescence	Company	Catalog No.
CD8	Alexa Fluor 488	Biolegend	344716
CD127	Alexa Fluor 647	Biolegend	351318
TIM-3	APC	R&D	FAB2365A
CD14	APC	BD	555399
IL-10	APC	BD	554707
CD38	APC	BD	345807
IFN-γ	APC	BD	554702
CXCR3	APC	BD	550967
CD4	APC-Cy7	Biolegend	317418
CD3	APC-Cy7	Biolegend	300318

PD-1	BB515	BD	564494
CD19	BB515	BD	564456
CD45RA	BB515	BD	564552
CD4	BB515	BD	564419
CXCR5	BV421	BD	562747
CD3	BV421	BD	562426
IFN-γ	BV421	Biolegend	506538
CCR4	BV421	Biolegend	359414
CD8	BV510	BD	563919
CD14	BV510	BD	563079
CD45	BV510	BD	563204
LIVE/DEAD	e450	invitrogen	65-0863-14
CD8	e450	invitrogen	48-0087-42
LIVE/DEAD	e500	invitrogen	L34966
IFN-γ	FITC	invitrogen	11-7319-82
CD16	PE	BD	555407
γδ TCR	PE	BD	555717
CCR6	PE	BD	551773
TNF	PE	invitrogen	12-7349-82
CD4	PE	invitrogen	12-0048-42
CD3	PE-CF594	BD	562280
CD206	PE-Cy5	BD	555136
IL-10	PE-Cy7	ebioscience	25-7108-42
CD25	PE-Cy7	BD	561405
CD56	PE-Cy7	Biolegend	362510
HLA-DR	PE-Cy7	Biolegend	307616

CCR7	PE-Cy7	Biolegend	353226
CD4	PE-Cy7	BD	560649
CD163	PE-Dazzle594	Biolegend	333624
CD45	PerCP	BD	340665
CD4	PerCP-Cy5.5	BD	560650
CD8	PerCP-Cy5.5	BD	565310
CD3	PerCP-Cy5.5	BD	340949
Fc block		Biolegend	422302

453

454 The following Cytometric Bead Array (CBA) products were used to detect cytokines:

Cytokine	Company	Catalog No.
Human Th1/Th2/Th17 kit (IL-10)	BD	560484
Human MCP-1 Flex Set	BD	558287

455

## 456 Single-Cell RNA library preparation and sequencing

457 Cell suspensions were loaded onto a chromium single-cell chip to generate single-458 cell gel bead-in-emulsions (GEMs) aiming for 2,000-8,000 single cells per reaction. 459 The single-cell 3'-library was constructed using Chromium Single Cell Reagent Kits 460 v3 (10X GENOMICS) following the manufacturer's user guide. Following cell lysis, 461 first-strand cDNA synthesis and amplification were carried out according to the 462 instructions. Amplified cDNA was purified using SPRIselect beads (Beckman Coulter) 463 and sheared to 250-400 bp. cDNA quality control was performed using Qubit 3.0 464 Fluorometer and Agilent Bioanalyzer 2100. The linear DNA libraries were converted to a single-stranded circular(ssCir) DNA library by MGI Easy Universal Library 465 466 Conversion Kit (App-A, MGI) and sequenced on BGISEQ-500 with high-throughput sequencing set (App-A, MGI) with the following read lengths: 28-bp read 1 467

468 (containing the 18-bp cell barcode and 10-bp randomer), 100-bp read 2 and 8-bp469 barcodes.

470

## 471 Single-cell RNA-seq data analysis

472 scRNA-seg data was processed using the scTE (https://github.com/iphe/scTE) 10x 473 pipeline, Briefly, reads were aligned to the human genome (hg38) using 474 STARsolo(Dobin et al., 2013) with the setting '--outSAMattributes NH HI AS nM CR 475 UY --readFilesCommand zcat --outFilterMultimapNmax CY UR 100 --476 winAnchorMultimapNmax 100 --outMultimapperOrder Random --runRNGseed 777 --477 outSAMmultNmax 1'. The default scTE parameters for 10x were used to get the 478 molecule count matrix. The count matrix was lightly filtered to exclude cell barcodes 479 with low numbers of counts: Cells with less than 1000 UMIs, less than 500 genes 480 detected or more than 20% fraction of mitochondrial counts were removed. For 481 comparison between patient PFMC, PBMC and control healthy PBMC, the batch effect was corrected by Seurat (V3)(Stuart et al., 2019). The genes with fold 482 483 change >1.5 and adjusted P-value <0.01 (Wilcoxon test) were considered to be differentially expressed. The Gene Ontology (GO) analysis was performed by 484 485 clusterProfiler(Yu et al., 2012). Other analysis was performed by SCANPY(Wolf et al., 486 2018).

487

#### 488 Ligand-receptor interaction analysis

489 The ligand-receptor interacting patterns annotation were downloaded from iMEX 490 consortium (http://www.imexconsortium.org/) (Orchard et al., 2012) and 491 CellPhoneDB (https://www.cellphonedb) (Vento-Tormo et al., 2018), we excluded 492 from our analysis with only secreted, cytokines, growth factors, hormones, 493 extracellular matrix, membrane, receptors and transporters according to uniport

494 classification. The cell-cell communication analysis followed the previous 495 pipeline(Vento-Tormo et al., 2018). We randomly permuted the cluster labels of all 496 cells 1,000 times and determined the mean of the average receptor expression level 497 of a cluster and the average ligand expression level of the interacting cluster. For 498 each receptor-ligand pair in each pairwise comparison between two cell types, this 499 generated a null distribution. We obtained a P-value for the likelihood of cell-type 500 specificity of a given receptor-ligand complex by t-test. We then prioritized the 501 interactions that are highly enriched between cell types based on the number of 502 significant pairs and selected anti-viral relevant ones.

503 **SUPPLEMENTAL INFORMATION** is linked to the online version of the paper.

504

#### 505 ACKNOWLEDGEMENTS

This study was funded by grants from the National Key Research and Development Program of China (2019YFA0110200, 2018YFC1200100, 2018ZX10301403), the special project for COVID-19 of Guangzhou Regenerative Medicine and Health Guangdong Laboratory(2020GZR110106006), the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology (2020YFC0841400) and Guangdong province (2020B111108001, 2018B020207013).

- 512 We thank the patient who took part in this study.
- 513

# 514 **AUTHOR CONTRIBUTIONS**

515 J.C., J.Z., J.Z. and Y.L. conceived and supervised the study, X.L., A.Z., Z.C., Y.X.,

- 516 F.Y., L.L., S.C., L.W., J.Z., F.L., D.C., R.C., N.Z., collected clinical specimen and
- 517 executed the experiments. J.H., L.L., H.F., B.C., Y.M., L.L., Z.Z., J.S., Y.W., Y.Z.,
- 518 X.W., X.Z., N.Z., Y.H., H.L., J-Y.W., J.W., X.X., X.C. did single cell sequencing and
- 519 bioinformatics analysis. J.C., J.Z., J.W. and J.Z. wrote the manuscript.

# 520 **REFERENCE**

- 521 Bermejo-Martin, J.F., Almansa, R., Menéndez, R., Mendez, R., Kelvin, D.J., and 522 Torres, A. (2020). Lymphopenic community acquired pneumonia as signature of 523 severe COVID-19 infection. Journal of Infection.
- 524 Biswas, R., Bunderson-Schelvan, M., and Holian, A. (2011). Potential role of the 525 inflammasome-derived inflammatory cytokines in pulmonary fibrosis. Pulm Med 526 *2011*, 105707.
- 527 Braciale, T.J., Sun, J., and Kim, T.S. (2012). Regulating the adaptive immune 528 response to respiratory virus infection. Nature Reviews Immunology *12*, 295-529 305.
- 530 Buhtoiarov, I.N., Lum, H., Berke, G., Paulnock, D.M., Sondel, P.M., and 531 Rakhmilevich, A.L. (2005). CD40 ligation activates murine macrophages via an 532 IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J 533 Immunol *174*, 6013-6022.
- 534 Chan, J.F.-W., Yuan, S., Kok, K.-H., To, K.K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip,
- 535 C.C.-Y., Poon, R.W.-S., *et al.* (2020). A familial cluster of pneumonia associated 536 with the 2019 novel coronavirus indicating person-to-person transmission: a
- 537 study of a family cluster. The Lancet *395*, 514-523.
- 538 Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K., and
- Perlman, S. (2016). Dysregulated Type I Interferon and Inflammatory MonocyteMacrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell
- 541 host & microbe *19*, 181-193.
- 542 Channappanavar, R., Fehr, A.R., Zheng, J., Wohlford-Lenane, C., Abrahante, J.E.,
- 543 Mack, M., Sompallae, R., McCray, P.B., Meyerholz, D.K., and Perlman, S. (2019).
- 544 IFN-I response timing relative to virus replication determines MERS coronavirus545 infection outcomes. Journal of Clinical Investigation *129*, 3625-3639.
- 546 Channappanavar, R., Zhao, J., and Perlman, S. (2014). T cell-mediated immune
  547 response to respiratory coronaviruses. Immunol Res *59*, 118-128.
- 548 Chen, J., and Subbarao, K. (2007). The Immunobiology of SARS\*. Annu Rev 549 Immunol *25*, 443-472.
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., *et al.* (2020). Epidemiological and clinical characteristics of 99 cases of 2019
  novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet *395*, 507-513.
- 554 Clark, E.A., and Lane, P.J. (1991). Regulation of human B-cell activation and 555 adhesion. Annu Rev Immunol *9*, 97-127.
- Contento, R.L., Molon, B., Boularan, C., Pozzan, T., Manes, S., Marullo, S., and Viola,
  A. (2008). CXCR4-CCR5: A couple modulating T cell functions. Proceedings of the
- 558 National Academy of Sciences *105*, 10101-10106.
- 559 Costantini, C., Bellet, M.M., Pariano, M., Renga, G., Stincardini, C., Goldstein, A.L.,
- Garaci, E., and Romani, L. (2019). A Reappraisal of Thymosin Alpha1 in CancerTherapy. Front Oncol 9, 873.
- 562 D'Ambrosio, D., Mariani, M., Panina-Bordignon, P., and Sinigaglia, F. (2001).
- 563 Chemokines and their receptors guiding T lymphocyte recruitment in lung
- 564 inflammation. Am J Respir Crit Care Med *164*, 1266-1275.
- 565 Dairaghi, D.J., Soo, K.S., Oldham, E.R., Premack, B.A., Kitamura, T., Bacon, K.B., and
- 566 Schall, T.J. (1998). RANTES-induced T cell activation correlates with CD3 567 expression. J Immunol *160*, 426-433.

- 568 Das, K.M., Lee, E.Y., Enani, M.A., AlJawder, S.E., Singh, R., Bashir, S., Al-Nakshbandi,
- N., AlDossari, K., and Larsson, S.G. (2015). CT correlation with outcomes in 15
  patients with acute Middle East respiratory syndrome coronavirus. AJR Am J
  Roentgenol *204*, 736-742.
- de Wit, E., van Doremalen, N., Falzarano, D., and Munster, V.J. (2016). SARS and
  MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14, 523-
- 575 MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 5 574 534.
- 575 Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., He, L., Chen, Y., Chen, H., Luo, W., *et* 576 *al.* (2018). LILRB4 signalling in leukaemia cells mediates T cell suppression and 577 tumour infiltration. Nature *562*, 605-609.
- Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., *et al.* (2020). Reduction and Functional Exhaustion of T Cells in Patients with
  Coronavirus Disease 2019 (COVID-19). medRxiv, 2020.2002.2018.20024364.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,
  Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner.
  Bioinformatics 29, 15-21.
- 584 Garaci, E., Lopez, M., Bonsignore, G., Della Giulia, M., D'Aprile, M., Favalli, C., Rasi, 585 Santini. S., Capomolla, Е., Vici, P., et al. (1995). Sequential G., 586 chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, 587 etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 31a, 2403-588 2405.
- Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E.,
  Uboldi, S., Zucchetti, M., Pasqualini, F., *et al.* (2013). Role of macrophage targeting
  in the antitumor activity of trabectedin. Cancer Cell *23*, 249-262.
- 592 Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L.,
- Hui, D.S.C., *et al.* (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med.
- Haas, K.M., Johnson, K.L., Phipps, J.P., and Do, C. (2018). CD22 Promotes B-1b Cell
  Responses to T Cell-Independent Type 2 Antigens. J Immunol 200, 1671-1681.
- Honey, K. (2006). CCL3 and CCL4 actively recruit CD8+ T cells. Nature ReviewsImmunology *6*, 427-427.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., *et al.* (2020). Clinical features of patients infected with 2019 novel coronavirus in
- 601 Wuhan, China. The Lancet *395*, 497-506.
- 602 Jacobs, J.F., Punt, C.J., Lesterhuis, W.J., Sutmuller, R.P., Brouwer, H.M., Scharenborg,
- N.M., Klasen, I.S., Hilbrands, L.B., Figdor, C.G., de Vries, I.J., *et al.* (2010). Dendritic
  cell vaccination in combination with anti-CD25 monoclonal antibody treatment:
  a phase I/II study in metastatic melanoma patients. Clin Cancer Res *16*, 5067-
- 606 5078.
- Jiang, J., Wang, X., Tian, J., Li, L., and Lin, Q. (2011). Thymosin plus cisplatin with
  vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review
  and meta-analysis of randomized controlled trials. Thorac Cancer 2, 213-220.
- 610 Jiang, Y., Li, Y., and Zhu, B. (2015). T-cell exhaustion in the tumor 611 microenvironment. Cell Death Dis *6*, e1792.
- 612 Le Bouteiller, P., Tabiasco, J., Polgar, B., Kozma, N., Giustiniani, J., Siewiera, J.,
- 613 Berrebi, A., Aguerre-Girr, M., Bensussan, A., and Jabrane-Ferrat, N. (2011). CD160:
- a unique activating NK cell receptor. Immunol Lett *138*, 93-96.
- 615 Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al.
- 616 (2020a). Coronavirus infections and immune responses. J Med Virol *92*, 424-432.

- 617 Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau,
- 618 E.H.Y., Wong, J.Y., *et al.* (2020b). Early Transmission Dynamics in Wuhan, China, of
- 619 Novel Coronavirus-Infected Pneumonia. The New England journal of medicine.
- 620 Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al.
- 621 (2020a). Longitudinal characteristics of lymphocyte responses and cytokine
- profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv,2020.2002.2016.20023671.
- 624 Liu, Q., Wang, R.S., Qu, G.Q., Wang, Y.Y., Liu, P., Zhu, Y.Z., Fei, G., Ren, L., Zhou, Y.W.,
- and Liu, L. (2020b). Gross examination report of a COVID-19 death autopsy. Fa Yi
  Xue Za Zhi *36*, 21-23.
- 627 Mahallawi, W.H., Khabour, O.F., Zhang, Q., Makhdoum, H.M., and Suliman, B.A.
- 628 (2018). MERS-CoV infection in humans is associated with a pro-inflammatory
  629 Th1 and Th17 cytokine profile. Cytokine *104*, 8-13.
- 630 Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002). Macrophage
- polarization: tumor-associated macrophages as a paradigm for polarized M2
   mononuclear phagocytes. Trends Immunol *23*, 549-555.
- 633 Murray, P.J. (2017). Macrophage Polarization. Annu Rev Physiol 79, 541-566.
- 634 Orchard, S., Kerrien, S., Abbani, S., Aranda, B., Bhate, J., Bidwell, S., Bridge, A.,
- Briganti, L., Brinkman, F.S.L., Cesareni, G., *et al.* (2012). Protein interaction data
  curation: the International Molecular Exchange (IMEx) consortium. Nature
  Methods 9, 345-350.
- 638 Orr, M.T., and Lanier, L.L. (2010). Natural killer cell education and tolerance. Cell
- 639 *142*, 847-856.
- 640 Page, C., Goicochea, L., Matthews, K., Zhang, Y., Klover, P., Holtzman, M.J.,
- Hennighausen, L., and Frieman, M. (2012). Induction of alternatively activatedmacrophages enhances pathogenesis during severe acute respiratory syndrome
- 643 coronavirus infection. J Virol *86*, 13334-13349.
- Pestka, S., Krause, C.D., Sarkar, D., Walter, M.R., Shi, Y., and Fisher, P.B. (2004).
  Interleukin-10 and related cytokines and receptors. Annu Rev Immunol *22*, 929979.
- 647 Porcel, J.M., and Light, R.W. (2006). Diagnostic approach to pleural effusion in 648 adults. Am Fam Physician *73*, 1211-1220.
- 649 Porcel, J.M., and Light, R.W. (2008). Pleural effusions due to pulmonary embolism.
  650 Curr Opin Pulm Med *14*, 337-342.
- 651 Shi, H., Han, X., Jiang, N., Cao, Y., Alwalid, O., Gu, J., Fan, Y., and Zheng, C. (2020).
- Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan,China: a descriptive study. The Lancet Infectious Diseases.
- 654 Sierra-Filardi, E., Nieto, C., Dominguez-Soto, A., Barroso, R., Sanchez-Mateos, P.,
- 655 Puig-Kroger, A., Lopez-Bravo, M., Joven, J., Ardavin, C., Rodriguez-Fernandez, J.L., 656 *et al.* (2014). CCL2 shapes macrophage polarization by GM-CSF and M-CSF:
- 657 identification of CCL2/CCR2-dependent gene expression profile. J Immunol 192,
- 658 3858-3867.
- 659 Stoger, J.L., Gijbels, M.J., van der Velden, S., Manca, M., van der Loos, C.M., Biessen,
- 660 E.A., Daemen, M.J., Lutgens, E., and de Winther, M.P. (2012). Distribution of
- macrophage polarization markers in human atherosclerosis. Atherosclerosis *225*,461-468.
- 663 Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd,
- Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. Cell *177*, 1888-1902 e1821.

- Svensson-Arvelund, J., Mehta, R.B., Lindau, R., Mirrasekhian, E., RodriguezMartinez, H., Berg, G., Lash, G.E., Jenmalm, M.C., and Ernerudh, J. (2015). The
  Human Fetal Placenta Promotes Tolerance against the Semiallogeneic Fetus by
- Inducing Regulatory T Cells and Homeostatic M2 Macrophages. The Journal ofImmunology *194*, 1534-1544.
- Tariq, M., Zhang, J., Liang, G., Ding, L., He, Q., and Yang, B. (2017). Macrophage
  Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in
  Breast Cancer. J Cell Biochem *118*, 2484-2501.
- Trifilo, M.J., Bergmann, C.C., Kuziel, W.A., and Lane, T.E. (2003). CC chemokine
- 675 ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following
  676 viral infection. J Virol 77, 4004-4014.
- 677 Vento-Tormo, R., Efremova, M., Botting, R.A., Turco, M.Y., Vento-Tormo, M., Meyer,
- K.B., Park, J.E., Stephenson, E., Polanski, K., Goncalves, A., *et al.* (2018). Single-cell
  reconstruction of the early maternal-fetal interface in humans. Nature *563*, 347353.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z.,
- King, Y., et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With
  2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama.
- Wang, Y., Smith, W., Hao, D., He, B., and Kong, L. (2019). M1 and M2 macrophage
  polarization and potentially therapeutic naturally occurring compounds.
  International Immunopharmacology *70*, 459-466.
- 687 Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam,
- S., Blattman, J.N., Barber, D.L., and Ahmed, R. (2007). Molecular signature of CD8+
  T cell exhaustion during chronic viral infection. Immunity *27*, 670-684.
- 690 Wolf, F.A., Angerer, P., and Theis, F.J. (2018). SCANPY: large-scale single-cell gene 691 expression data analysis. Genome Biol *19*, 15.
- Wong, C.K., Lam, C.W., Wu, A.K., Ip, W.K., Lee, N.L., Chan, I.H., Lit, L.C., Hui, D.S.,
  Chan, M.H., Chung, S.S., *et al.* (2004). Plasma inflammatory cytokines and
  chemokines in severe acute respiratory syndrome. Clin Exp Immunol *136*, 95103.
- 696 Yi, J.S., Cox, M.A., and Zajac, A.J. (2010). T-cell exhaustion: characteristics, causes697 and conversion. Immunology *129*, 474-481.
- Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R package for
  comparing biological themes among gene clusters. OMICS *16*, 284-287.
- Zhang, Y., Du, W., Chen, Z., and Xiang, C. (2017). Upregulation of PD-L1 by SPP1
  mediates macrophage polarization and facilitates immune escape in lung
  adenocarcinoma. Experimental Cell Research *359*, 449-457.
- 703 Zhao, J., Alshukairi, A.N., Baharoon, S.A., Ahmed, W.A., Bokhari, A.A., Nehdi, A.M.,
- Layqah, L.A., Alghamdi, M.G., Al Gethamy, M.M., Dada, A.M., *et al.* (2017). Recovery from the Middle East respiratory syndrome is associated with antibody and T-
- 706 cell responses. Science immunology 2.
- 707 Zhao, J., Zhao, J., Mangalam, A.K., Channappanavar, R., Fett, C., Meyerholz, D.K.,
- Agnihothram, S., Baric, R.S., David, C.S., and Perlman, S. (2016). Airway Memory
- 709 CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory
  710 Coronaviruses. Immunity 44, 1379-1391.
- 710 Coronaviruses. Immunity 44, 1379-1391.
- Zhao, J., Zhao, J., and Perlman, S. (2010). T cell responses are required for
  protection from clinical disease and for virus clearance in severe acute
  respiratory syndrome coronavirus-infected mice. Journal of virology *84*, 9318-
- 714 9325.

- 715 Zhao, J., Zhao, J., Van Rooijen, N., and Perlman, S. (2009). Evasion by stealth:
- inefficient immune activation underlies poor T cell response and severe disease
- 717 in SARS-CoV-infected mice. PLoS pathogens 5, e1000636.
- 718 Zheng, G.X., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B.,
- 719 Wheeler, T.D., McDermott, G.P., Zhu, J., *et al.* (2017). Massively parallel digital 720 transcriptional profiling of single cells. Nat Commun *8*, 14049.
- 721 Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B.,
- Huang, C.L., *et al.* (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature *579*, 270-273.
- Zollo, M., Di Dato, V., Spano, D., De Martino, D., Liguori, L., Marino, N., Vastolo, V.,
- Navas, L., Garrone, B., Mangano, G., *et al.* (2012). Targeting monocyte chemotactic
- 726 protein-1 synthesis with bindarit induces tumor regression in prostate and
- 727 breast cancer animal models. Clin Exp Metastasis *29*, 585-601.
- 728

# Table S2

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
severity	severe	severe	mild	mild	severe
Age	40s	50s	20s	50s	40s
Gender	male	male	female	male	male
Wuhan exposure history	Yes	Yes	Yes	No	Yes
Symptom onset day	2020.01.22	2020.01.20	2020.02.06	2020.02.02	2020.01.26
Fever/Cough	Yes	Yes	Yes	Yes	Yes
Hospitalization data	2020.01.28- Present	2020.01.22-Present	2020.02.08-2020.02.21	2020.02.02-2020.04.09	2020.01.29-2020.03.26
Intensive Care	2020.01.31-2020.03.09	2020.01.23-Present	No	No	2020.02.15-2020.03.09
Sputum sampling date (scRNA-seq)	2020.02.14	2020.02.14	2020.02.14	2020.02.14	No
Sputum sampling date (FACS)	No	No	2020.02.20	2020.02.20	2020.02.20; 2020.03.03; 2020.03.24
Prednisone (泼尼松)	Yes	No	No	No	Yes
Methylprednisolone(甲强龙)	Yes	Yes	No	No	No
Zadaxin (日达仙)	No	Yes	No	No	Yes
γ-Immunoglobulin (丙球)	No	Yes	No	No	Yes